A Dynamic HIV-Transmission Model for Evaluating the Costs and Benefits of Vaccine Programs

References

• Anderson R. M. , Gupta S. , May R. M. Potential of community-wide chemotherapy or immunotherapy to control the spread of HIV-1. Nature (1991) 350 6316 356 359 Crossref, Google Scholar
• Beck J. R. , Pauker S. G. The Markov process in medical prognosis. Medical Decision Making (1983) 3 4 419 458 Crossref, Google Scholar
• Blower S. M. , McLean A. R. Prophylactic vaccines, risk behavior change, and the probability of eradicating HIV in San Francisco. Science (1994) 265 5117 1451 1454 Crossref, Google Scholar
• Brandeau M. L. , Owens D. K. , Brandeau M. L. , Kaplan E. H. When women return to risk: Costs and benefits of HIV screening in the presence of relapse. Modeling the AIDS Epidemic: Planning, Policy and Prediction (1994) (Raven Press, New York) 121 136 Google Scholar
• Brandeau M. L. , Owens D. K. , Sox C. H. , Wachter R. M. Screening women of childbearing age for human immunodefi-ciency virus: A cost-benefit analysis. Arch. Internal Medicine (1992) 152 2229 2237 Crossref, Google Scholar
• Brandeau M. L. , Owens D. K. , Sox C. H. , Wachter R. M. Screening women of childbearing age for human immunodefi-ciency virus: A model-based policy analysis. Management Sci. (1993) 39 1 72 92 Link, Google Scholar
• Chan C. M. , Oreglia A. California Life Expectancy: Abridged Life Tables for California and Los Angeles County 1989–91 (1993) (California Department of Health Services, California) . Sacramento, August Google Scholar
• Cohen J. HIV vaccines: Are researchers racing toward success, or crawling? Science (1994) 265 5177 1373 1375 Crossref, Google Scholar
• Communication Technologies in association with the San Francisco AIDS Foundation HIV-related knowledge, attitudes, and behaviors among San Francisco gay and bisexual men: Results from the fifth population-based survey. (1990) . San Francisco Department of Public Health report, January 30 Google Scholar
• DiClemente R. J. , Wingood G. M. A randomized controlled trial of an HIV sexual risk-reduction intervention for young African-American women. J. Amer. Medical Assoc. (1995) 274 16 1271 1276 Crossref, Google Scholar
• Dolin R. , Graham B. S. , Greenberg S. B. , Tacket C. O. , Belshe R. B. , Midthun K. , Clements M. L. , Gorse G. J. , Horgan B. W. , Atmar R. L. , Karzon D. T. , Bonnez W. , Fernie B. F. , Montefiori D. C. , Stablein D. M. , Smith G. E. , Koff W. C. NIAD AIDS Vaccine Clinical Trials Network The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) re-combinant gp160 candidate vaccine in humans. Ann. Internal Medicine (1991) 114 2 119 127 Crossref, Google Scholar
• Edwards D. M. A cost-effectiveness analysis of potential preventive and therapeutic HIV vaccines. (1995) . PhD thesis, Department of Engineering-Economic Systems, Stanford University Google Scholar
• Edwards D. M. , Shachter R. D. , Owens D. K. Comparison of methods for valuing health and economic effects of interventions with delayed outcomes: Application to HIV vaccine programs. Medical Decision Making (1995a) 15 4 420 Google Scholar
• Edwards D. M. , Shachter R. D. , Owens D. K. Cost effectiveness of preventive and therapeutic HIV vaccines: Implications for vaccine development. Medical Decision Making (1995b) 15 4 420 . (abstract) Google Scholar
• Graham B. S. , Keefer M. C. , McElrath J. , Gorse G. J. , Schwartz D. H. , Weinhold K. , Matthews T. J. , Sinangil F. , Esterlitz J. R. , Fast P. E. Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: Recombinant glycoprotein (rgp) 120. Ann. Internal Medicine (1996) 125 4 270 279 Crossref, Google Scholar
• Graham B. S. , Wright P. F. Candidate AIDS vaccines. New England J. Medicine (1995) 333 20 1331 1339 Crossref, Google Scholar
• Haynes B. F. Scientific and social issues of human immunodeficiency virus vaccine development. Science (1993) 260 5112 1279 1286 Crossref, Google Scholar
• Haynes B. F. , Pantaleo G. , Fauci A. S. Toward an understanding of the correlates of protective immunity to HIV infection. Science (1996) 271 5247 324 328 Crossref, Google Scholar
• Hellinger F. J. Forecasts of the costs of medical care for persons with HIV: 1992–1995. Inquiry (1992) 29 3 356 365 Google Scholar
• Hellinger F. J. The lifetime cost of treating a person with HIV. J. Amer. Medical Assoc. (1993) 270 4 474 478 Crossref, Google Scholar
• Laumann E. O. , Gagnon J. H. , Michael R. T. , Michaels S. The Social Organization of Sexuality: Sexual Practices in the United States (1994) (The University of Chicago Press, Chicago, Illinois) Google Scholar
• Lemp G. F. , Payne S. F. , Rutherford G. W. , Hessol N. A. , Winkelstein W. J. , Wiley J. A. , Moss A. R. , Chaisson R. E. , Chen R. T. , Feigal D. W. J. , Thomas P. A. , Werdegar D. Projections of AIDS morbidity and mortality in San Francisco. J. Amer. Medical Assoc. (1990) 263 11 1497 1501 Crossref, Google Scholar
• Longini I. M. , Clark W. S. , Byers R. H. , Ward J. W. , Darrow W. W. , Lemp G. F. , Hethcote H. W. Statistical analysis of the stages of HIV infection using a Markov model. Statist. Medicine (1989) 8 7 831 843 Crossref, Google Scholar
• The Student Edition of MATLAB (1992) (Prentice Hall, Englewood Cliffs, New Jersey) . The MathWorks, I Google Scholar
• MATLAB. (1994) (The MathWorks, Inc., Natick, Massachusetts) . The MathWorks, I, version 4.2c for UNIX Google Scholar
• McLean A. R. , Blower S. M. Imperfect vaccines and herd immunity to HIV. Proc. Royal Society of London. Series B: Biological Sciences (1993) 253 9 13 Crossref, Google Scholar
• Newcomb M. , Liu W. , Officer C. , Hulbert L. , Wallis J. , Richmond K. , Richmond B. Stella II. (1996) (High Performance Systems, Inc., Hanover, New Hampshire) . PC version 3.0.7 for Windows Google Scholar
• Owens D. K. , Cardinalli A. B. , Nease R. F. Physicians' assessments of the utility of health states associated with human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infection. Quality of Life Res. (1997) 6 1 77 86 Crossref, Google Scholar
• Owens D. K. , Edwards D. M. , Shachter R. Population effects of preventive and therapeutic HIV vaccine in early- and late-stage epidemics. (1996) . Report no. SMI-97-0674, Department of Medicine, Section on Medical Informatics, Stanford University Google Scholar
• Owens D. K. , Harris R. A. , Scott P. M. , Nease R. F. Screening surgeons for HIV infection: A cost-effectiveness analysis. Ann. Internal Medicine (1995) 122 9 641 652 Crossref, Google Scholar
• Owens D. K. , Nease R. F. , Brandeau M. L. , Kaplan E. H. Transmission of human immunodeficiency virus (HIV) infection between provider and patient: A quantitative analysis of risk. Modeling the AIDS Epidemic: Planning, Policy and Prediction (1994) (Raven Press, New York) 153 177 Google Scholar
• Owens D. K. , Sox H. C. , Shortliffe E. H. , Perreault L. E. , Fagan L. M. , Wiederhold G. Medical decision making: Probabilistic medical reasoning. Medical Informatics: Computer Applications in Health Care (1990) (Addison-Wesley, Reading, Massachusetts) 70 116 Google Scholar
• Paltiel A. D. , Brandeau M. L. , Kaplan E. H. Timing is of the essence: Matching AIDS policy to the epidemic life cycle. Modeling the AIDS Epidemic: Planning, Policy and Prediction (1994) (Raven Press, New York) 53 72 Google Scholar
• Paltiel A. D. , Kaplan E. H. Modeling zidovudine therapy: A cost-effectiveness analysis. J. Acquired Immune Deficiency Syndromes (1991) 4 8 795 804 Google Scholar
• Paltiel A. D. , Kaplan E. H. The epidemiological and economic consequences of AIDS clinical trials. J. Acquired Immune Deficiency Syndromes (1993) 6 2 179 190 Google Scholar
• Redfield R. R. , Birx D. L. , Ketter N. , Tramont E. , Polonis V. , Davis C. , Brundage J. F. , Smith G. , Johnson S. , Fowler A. , Wierzba T. , Shafferman A. , Volvovitz F. , Oster C. , Burke D. S. Military Medical Consortium for Applied Retroviral Research A phase I evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with early human immunodeficiency virus infection. New England J. Medicine (1991) 324 24 1677 1684 Crossref, Google Scholar
• Samuel M. C. , Mohr M. S. , Speed T. P. , Winkelstein W. , Brandeau M. L. , Kaplan E. H. Infectivity of HIV by anal and oral intercourse among homosexual men: Estimates from a prospective study in San Francisco. Modeling the AIDS Epidemic: Planning, Policy and Prediction (1994) (Raven Press, New York) 423 438 Google Scholar
• San Francisco Department of Public Health HIV incidence and prevalence in San Francisco in 1992: Summary report from an HIV consensus meeting. (1992) (San Francisco Department of Public Health, San Francisco, California) 3 . February 2 Google Scholar
• San Francisco Department of Public Health AIDS Surveillance Report. (1995) (San Francisco Department of Public Health, San Francisco, California) 3 . April 30 Google Scholar
• Shepard D. S. , Thompson M. S. First principles of cost-effectiveness analysis in health. Public Health Rep. (1979) 94 6 535 543 Google Scholar
• Sonnenberg F. A. , Beck J. R. Markov models in medical decision making: A practical guide. Medical Decision Making (1993) 13 4 322 338 Crossref, Google Scholar
• Trussell J. , Hatcher R. A. , Cates W. , Stewart F. H. , Kost K. A guide to interpreting contraceptive efficacy studies. Obstetrics and Gynecology (1990) 76 3 558 67 . pt. 2 Google Scholar
• Weinstein M. C. , Stason W. B. Foundations of cost-effectiveness analysis for health and medical practices. New England J. Medicine (1977) 296 13 716 721 Crossref, Google Scholar
• WHO/UNAIDS The current global situation of AIDS. (1996) . World Health Organization (available from the Regional Program on AIDS/STD, Pan American Health Organization, 525 23rd St. NW, Washington, DC 20037-2847), June 30 Google Scholar
• Wintsch J. , Chaignat C.-L. , Braun D. G. , Jeannet M. , Stalder H. , Abrignani S. , Montagna D. , Clavijo F. , Moret P. , Dayer J.-M. , Staehelin T. , Doe B. , Steimer K. S. , Dina D. , Cruchaud A. Safety and immunogenicity of a genetically engineered human immunodeficiency virus vaccine. J. Infectious Diseases (1991) 163 2 219 225 Crossref, Google Scholar
• World Health Organization Scientific and public health rationale for HIV vaccine efficacy trials. AIDS (1995) 9 3 WHO1 WHO4 Google Scholar